Advisors Preferred LLC Takes $2.93 Million Position in Phibro Animal Health Corporation $PAHC

Advisors Preferred LLC acquired a new stake in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) in the first quarter, HoldingsChannel reports. The fund acquired 52,998 shares of the company’s stock, valued at approximately $2,931,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. 1620 Investment Advisors Inc. lifted its holdings in Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after acquiring an additional 295 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after acquiring an additional 386 shares during the period. Rothschild Investment LLC grew its position in shares of Phibro Animal Health by 2,500.0% during the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after acquiring an additional 1,000 shares during the last quarter. iSAM Funds UK Ltd bought a new position in shares of Phibro Animal Health during the third quarter worth about $61,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Phibro Animal Health by 7,671.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after acquiring an additional 2,685 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Price Performance

Shares of NASDAQ PAHC opened at $33.04 on Wednesday. Phibro Animal Health Corporation has a twelve month low of $25.58 and a twelve month high of $60.08. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97. The firm has a 50-day moving average of $33.45 and a two-hundred day moving average of $43.51. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of 14.18, a PEG ratio of 0.46 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The company had revenue of $383.54 million for the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, analysts expect that Phibro Animal Health Corporation will post 3.08 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd were given a $0.12 dividend. The ex-dividend date was Wednesday, June 3rd. This represents a $0.48 annualized dividend and a yield of 1.5%. Phibro Animal Health’s payout ratio is 20.60%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PAHC. Citigroup cut their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Wall Street Zen cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings downgraded Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $42.50.

Insider Activity

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $55.80, for a total value of $392,832.00. Following the transaction, the chief executive officer owned 67,720 shares of the company’s stock, valued at approximately $3,778,776. This represents a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 39,728 shares of company stock valued at $2,144,299 over the last quarter. 50.13% of the stock is currently owned by corporate insiders.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.